Glucocerebroside treatment of disease
US10639324B2 · kind B2 · utility
0Cited by
15References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2018 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | Oct 30, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.